| Literature DB >> 33301016 |
Hossein Amini1, Masoud Solaymani-Dodaran2,3, Batool Mousavi4, Seyed Nooredin Alam Beladi4, Mohammad Reza Soroush4, Jamileh Abolghasemi5, Amir Vahedian-Azimi6, Mahmoud Salesi7, Paul C Guest8, Amirhossein Sahebkar9,10,11, Mostafa Ghanei7.
Abstract
Importance: The prevalence and severity of long-term health complications after exposure to sulfur mustard are unknown. Objective: To investigate the long-term health outcomes among survivors exposed to sulfur mustard during the Iran-Iraq War. Design, Setting, and Participants: In this retrospective cohort study, late-onset health complications of 64 190 Iranian survivors exposed to sulfur mustard during the Iran-Iraq War from 1980 to 1988 were investigated using descriptive statistics. Data involving affected organs and symptom severity were extracted from the Veterans and Martyr Affair Foundation (VMAF) database from 1980 to 2019. Assessments were conducted across 3 groups depending on whether survivors were (1) evacuated and admitted (EA) to a hospital; (2) not evacuated or admitted (NEA) to a hospital; or (3) evacuation or admission status was not documented. Exposures: Analysis of chronic symptom severity following exposure to sulfur mustard. Main Outcomes and Measures: Mild, moderate, or severe rankings of symptoms in lungs, eyes, and skin of survivors exposed to sulfur mustard using data from the VMAF database.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33301016 PMCID: PMC7729433 DOI: 10.1001/jamanetworkopen.2020.28894
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Distributions of Sulfur Mustard Injuries Among Study Population by Age at Time of Exposure and Sex
| Lesion category | No. (%) of exposed survivors | ||||||
|---|---|---|---|---|---|---|---|
| Male age, y | Female age, y | Total | |||||
| ≤21 | >21 | All | ≤21 | >21 | All | ||
| None | 9726 (38.6) | 8075 (37.2) | 17 801 (38.0) | 134 (32.1) | 142 (27.2) | 276 (29.4) | 18 077 (37.8) |
| Mild | 12 761 (50.6) | 10 626 (49.0) | 23 387 (49.9) | 225 (54.0) | 310 (59.3) | 535 (56.9) | 23 922 (50.0) |
| Moderate | 2435 (9.7) | 2691 (12.4) | 5126 (10.9) | 52 (12.5) | 66 (12.6) | 118 (12.6) | 5244 (11.0) |
| Severe | 274 (1.1) | 301 (1.4) | 575 (1.2) | 6 (1.4) | 5 (1.0) | 11 (1.2) | 586 (1.2) |
| Total | 25 196 (100) | 21 693 (100) | 46 889 (100) | 417 (100) | 523 (100) | 940 (100) | 47 829 (100) |
| <.001 | <.001 | ||||||
Distribution of Lesions in Injured Organs According to Age, Sex, and Injury Severity
| Symptom category | Eye, No. (%) of exposed survivors | Skin, No. (%) of exposed survivors | Lung, No. (%) of exposed survivors | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y | Sex | Age, y | Sex | Age, y | Sex | |||||||||
| ≤21 | >21 | Male | Female | ≤21 | >21 | Male | Female | ≤21 | >21 | Male | Female | |||
| None | 21 816 (85.2) | 19 022 (85.6) | 51 546 (86.4) | 1086 (89.5) | 22 950 (89.6) | 19 728 (88.8) | 53 344 (89.4) | 975 (80.4) | 12 131 (47.4) | 10 159 (45.7) | 29 138 (48.8) | 449 (37.0) | ||
| Mild | 3635 (14.2) | 3059 (13.8) | 7750 (13.0) | 124 (10.2) | 2380 (9.3) | 2190 (9.9) | 5626 (9.4) | 191 (15.7) | 10 977 (42.9) | 9246 (41.6) | 24 110 (40.4) | 624 (51.4) | ||
| Moderate | 63 (0.2) | 74 (0.3) | 172 (0.3) | 3 (0.2) | 242 (0.9) | 252 (1.1) | 581 (1.0) | 40 (3.3) | 2341 (9.1) | 2599 (11.7) | 5906 (9.9) | 130 (10.7) | ||
| Severe | 99 (0.4) | 61 (0.3) | 180 (0.3) | 0 | 41 (0.2) | 46 (0.2) | 97 (0.2) | 7 (0.6) | 164 (0.6) | 212 (1.0) | 494 (0.8) | 10 (0.8) | ||
| Total | 25 613 (100) | 22 216 (100) | 59 648 (100) | 1213 (100) | 25 613 (100) | 22 216 (100) | 59 648 (100) | 1213 (100) | 25 613 (100) | 22 216 (100) | 59 648 (100) | 1213 (100) | ||
| <.001 | <.001 | <.001 | <.001 | <.001 | <.001 | |||||||||
Characteristics of Study Population According to Injured Organ and Documented Exposure Level
| Characteristic | No. (%) of exposed survivors | ||
|---|---|---|---|
| Evacuated and admitted | Not evacuated or admitted | Total | |
| Age group, y | |||
| ≤21 | 13 540 (53.8) | 12 073 (53.2) | 25 155 (52.6) |
| >21 | 11 615(46.2) | 10 601 (46.8) | 22 674 (47.4) |
| Total | 25 155 (100) | 22 674 (100) | 47 829 (100) |
| Sex | |||
| Male | 31 781 (98.7) | 27 867 (97.1) | 59 648 (98) |
| Female | 393 (1.3) | 820 (2.9) | 1213 (2) |
| Total | 32 174 (100) | 28 687 (100) | 60 861(100) |
| Lesion | |||
| Late lung | |||
| None | 24 766 (77) | 4821 (16.8) | 29 587 (48.6) |
| Mild | 3536 (11) | 21 198 (73.9) | 24 734 (40.6) |
| Moderate | 3378 (10.5) | 2658 (9.3) | 6036 (9.9) |
| Severe | 494 (1.5) | 10 (0) | 504 (0.8) |
| Late skin | |||
| None | 27 164 (84.4) | 27 155 (94.7) | 54 319 (89.3) |
| Mild | 4435 (13.8) | 1382 (4.8) | 5817 (9.6) |
| Moderate | 484 (1.5) | 137 (0.5) | 621 (1) |
| Severe | 91 (0.3) | 13 (0) | 104 (0.2) |
| Late eye | |||
| None | 25 194 (78.3) | 27 438 (95.6) | 52 632 (86.5) |
| Mild | 6683 (20.8) | 1191 (4.2) | 7874 (12.9) |
| Moderate | 135 (0.4) | 40 (0.1) | 175 (0.3) |
| Severe | 162 (0.5) | 18 (0.1) | 180 (0.3) |
| <.001 | <.001 | ||
Figure. Proportion of Lung, Eye, and Skin Moderate and Severe Late Complications of Sulfur Mustard in 31 Iranian Provinces
Light purple indicates less than 10%; purple, between 10% and 13%; and dark purple, more than 13%.